Sirolimus-eluting versus bare-metal stent implantation in patients with ostial lesions.
To investigate the efficacy of implantation of sirolimus-eluting stents (SES) in the ostium of coronary arteries. We assigned 96 patients with lesions located in ostias of the coronary circulation to receive a SES or a bare-metal stent (BMS). At follow-up the late lumen loss was 0.07 mm in the SES versus 1.06 mm in the BMS group (p<0.001); -0.04 mm versus 0.11 mm (p = 0.12) in the neighbour ostium. The rate of target lesion revascularisation was 2% with SES and 39% with BMS (p<0.001), and major adverse cardiac events (MACE) 6% versus 41% (p = 0.001). In patients with ostial coronary lesions the angiographic outcome is improved and the long-term MACE rate is low after SES compared with BMS implantation.